Pfizer Appoints Jeffrey Legos as Chief Oncology Officer
Legos will take over from Roger Dansey, who will begin transitioning to retirement.
Image Credit: Adobe Stock Images/Din Nasahrudin
Pfizer announced that it has appointed Jeffrey Legos, PhD, MBA, as its new chief oncology officer, succeeding Roger Dansey, MD, who will retire. According to the company, Legos will lead Pfizer’s oncology R&D division, overseeing all stages from preclinical to late-stage clinical development. Legos will report to Chris Boshoff, MD, PhD, chief scientific officer, president, Pfizer R&D.
Legos’s most recent role was as EVP, global head of oncology and hematology development for Novartis. According to Pfizer, Legos joins with over 20 years of experience in securing more than 40 global regulatory approvals for oncology drugs and companion diagnostics. Legos also contributed to the establishment of GSK’s oncology business unit as VP and global medicines development leader in oncology.
Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written over 40 manuscripts and abstracts for peer-reviewed journals. Further, he currently serves as a scientific advisor to the Melanoma Research Alliance, a strategic advisory board member for Gingko Bioworks.
Lykos Therapeutics Reshuffles Board of Directors Following FDA Rejection of Midomafetamine Capsules
January 15th 2025During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.
